AB43: Bill Text

AB43,2 Section 2. 450.01 (16) (L) of the statutes is created to read:

AB43,3,9 450.01 (16) (L) Prescribing and dispensing hormonal contraceptive patches and self-administered oral hormonal contraceptives pursuant to s. 450.095 (2m).

AB43,3 Section 3. 450.095 (title) of the statutes is amended to read:

AB43,3,12 450.095 (title) Duty to dispense Prescribing and dispensing of contraceptives.

AB43,4 Section 4. 450.095 (1) (ag) and (ar) of the statutes are created to read:

AB43,3,17 450.095 (1) (ag) “Hormonal contraceptive patch” means a transdermal patch applied to the skin of a patient, by the patient or by a practitioner, that releases a drug composed of a combination of hormones that is approved by the federal food and drug administration to prevent pregnancy.

AB43,3,21 (ar) “Self-administered oral hormonal contraceptive” means a drug composed of a combination of hormones that is approved by the federal food and drug administration to prevent pregnancy and that the patient to whom the drug is prescribed may take orally.

AB43,5 Section 5. 450.095 (2m) of the statutes is created to read:

AB43,4,3 450.095 (2m) (a) In accordance with rules promulgated by the board, a pharmacist may prescribe and dispense hormonal contraceptive patches and self- administered oral hormonal contraceptives to a person who is at least 18 years of age.

AB43,4,8 (b) 1. The board shall, after consultation with the medical examining board, the board of nursing, and the department of health services, promulgate rules to establish standard procedures for the prescribing of hormonal contraceptive patches and self-administered oral hormonal contraceptives by pharmacists under this subsection.

AB43,4,12 2. a. The rules promulgated under subd. 1. shall include a self-assessment questionnaire, developed in consideration of guidelines established by the American Congress of Obstetricians and Gynecologists, that must be used by a pharmacist as described in subd. 3. a.

AB43,4,17 b. The self-assessment questionnaire shall state and the patient shall acknowledge on the self-assessment questionnaire that a hormonal contraceptive patch or a self-administered oral hormonal contraceptive is not protection against sexually transmitted diseases, which may have a significant negative impact on reproductive and general health.

AB43,4,21 c. The patient shall acknowledge on the self-assessment questionnaire that it is strongly recommended that the patient annually meet with a physician or other medical professional to discuss the patient’s prescribed hormonal contraceptive treatment and other routine preventive care.

AB43,4,23 3. The rules promulgated under subd. 1. shall require a pharmacist to do all of the following:

AB43,5,3 a. Provide the self-assessment questionnaire described in subd. 2. to a patient prior to the pharmacist’s prescribing the hormonal contraceptive patch or self- administered oral hormonal contraceptive to the patient.

AB43,5,6 b. Report to the patient’s primary care practitioner upon prescribing and dispensing the hormonal contraceptive patch or self-administered oral hormonal contraceptive.

AB43,5,8 c. Provide the patient with a written record of the hormonal contraceptive patch or self-administered oral hormonal contraceptive prescribed and dispensed.

AB43,5,11 d. Dispense the hormonal contraceptive patch or self-administered oral hormonal contraceptive to the patient as soon as practicable after the pharmacist issues the prescription order.

AB43,5,14 4. The rules promulgated under subd. 1. shall prohibit a pharmacist from prescribing and dispensing a hormonal contraceptive patch or self-administered oral hormonal contraceptive to a patient unless all of the following apply:

AB43,5,16 a. The patient has responded to the self-assessment questionnaire provided under subd. 3. a. and undergone a blood pressure screening.

AB43,5,19 b. The use of the hormonal contraceptive patch or self-administered oral hormonal contraceptive by the patient is not contraindicated based upon the results of the questionnaire and screening.

AB43,6,2 5. The rules promulgated under subd. 1. shall permit any qualified pharmacy employee to provide a self-assessment questionnaire required under subd. 3. a. and administer a blood pressure screening required under subd. 4. a. if a pharmacist reviews the results of the self-assessment questionnaire and the blood pressure screening before prescribing and dispensing any hormonal contraceptive path or self-administered oral hormonal contraceptive to a patient.

AB43,6,5 (c) Any pharmacist who prescribes hormonal contraceptives under this subsection shall have in effect malpractice liability insurance coverage evidenced by one of the following:

AB43,6,7 1. Personal liability coverage in the amounts specified for health care providers under s. 655.23 (4).

AB43,6,9 2. Coverage under a group liability policy providing individual coverage for the pharmacist under s. 655.23 (4).

AB43,6 Section 6. 450.095 (3) of the statutes is amended to read:

AB43,6,13 450.095 (3) Any person who violates this section or any rules promulgated under this section may be required to forfeit not less than $250 nor more than $2,500 for each violation.

AB43,7 Section 7. Nonstatutory provisions.

AB43,6,23 (1) The pharmacy examining board may promulgate emergency rules under s. 227.24 necessary to implement this act. Notwithstanding s. 227.24 (1) (c) and (2), emergency rules promulgated under this subsection remain in effect until May 1, 2027, or the date on which permanent rules take effect, whichever is sooner. Notwithstanding s. 227.24 (1) (a) and (3), the examining board is not required to provide evidence that promulgating a rule under this subsection as an emergency rule is necessary for the preservation of the public peace, health, safety, or welfare and is not required to provide a finding of emergency for a rule promulgated under this subsection.

AB43,8 Section 8. Effective dates. This act takes effect on January 1, 2026, except as follows:

AB43,7,3 (1) Section 7 (1) of this act takes effect on the day after publication.

AB43,7,4 (end)